Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and…
<!-- Name:DistributionId Value:8836312 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Cingulate
Cingulate Announces Positive Top-Line Results from Fed/Fast Study of Lead Asset…
<!-- Name:DistributionId Value:8755907 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Cingulate Completes Fed/Fast Study Assessing Food Effect with CTx-1301, Lead…
KANSAS CITY, Kan., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery…
Cingulate Announces Agreement with Societal CDMO and Provides Clinical Update
KANSAS CITY, Kan., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery…
Cingulate Presents Data for Its Triple-Release Buspirone Product Candidate: CTx-2103
Data Demonstrated Ability of CTx-2103 to Deliver a Single Administration of Triple-Release Buspirone – Setting the Stage for Future Trials Employing Cingulate’s Precision Timed Release™…
Cingulate to Participate in Benzinga All Live Access Event
KANSAS CITY, Kan., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™)…
Cingulate to Present at H.C. Wainwright Global Investment Conference
KANSAS CITY, Kan., May 18, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™)…
Cingulate Provides 2022 Clinical Plan for CTx-1301, an Investigational Medication for…
KANSAS CITY, Kan., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™)…